Background: Myocardial infarction is more likely if the heart damage biomarker cardiac troponin T (cTnT) is elevated in a blood sample, indicating that cardiac damage has occurred. No method allows the clinician to estimate the risk of myocardial infarction at a specific cTnT level in a given patient.
Introduction
The clinical utility of a biomarker is often evaluated using binary classification that results in a fraction of patients with or without the disease below or above a given biomarker level [1] [2] [3] [4] [5] [6] . Some examples are sensitivity (Sn) and specificity (Sp), where patients with or without disease are analyzed separately (Fig. 1A) , and negative and positive predictive values (NPV and PPV), where patients with and without disease are analyzed together ( Fig. 1A and Supplemental Tables 1 and 2 ).
An emergency room physician assessing the result of the heart damage biomarker cardiac troponin T (cTnT) in a patient with chest pain is often occupied with the following two questions:
1. If I exclude using the cTnT level in my patient, what fraction of patients with myocardial infarction (MI) will I miss? 2. At the patient level of cTnT, what is the probability of MI?
The answer to the first question is simply 1-Sn at the patient's cTnT level; that is, the fraction of patients with MI presenting with cTnT levels below the actual patient's level.
The probability of disease at a given cTnT level is more complicated. The MI prevalence at a specific cTnT level increases along with the pretest MI prevalence, and is increased by age, smoking habits, male sex and so forth [7] . Therefore, to answer how likely it is that this particular patient has an MI, the calculations must also involve an estimate of the patient's pre-test prevalence of MI.
Unfortunately, most binary classifications do not adjust for the pretest prevalence of disease. In addition, binary classification results in a fraction with disease above or below a given biomarker level, not the probability of disease at the patient's biomarker level ( Fig. 1B ).
There are ways to use binary classification in a pre-test prevalencesensitive manner, such as the likelihood ratio combined with Bayesian reasoning [8] and prevalence-adjusted predictive values [9, 10] .
However, like all binary classification, these calculations use the fraction of patients above or below a given biomarker level and hence fail to estimate the prevalence of disease at a specific biomarker level ( Fig. 1B) . Slopes calculated from an ROC plot is one way to do this [11, 12] . However, this method has not been extensively used.
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At present, common methods using binary classification are unable to calculate the answer to the clinician's second question: "What is the risk of MI at my patient's level of cTnT?".
Here, we describe a parameter that makes it possible to calculate the probability of disease at a specific biomarker level, predictive value among lookalikes (PAL). The PAL is calculated using the pre-test prevalence in combination with Sn and Sp between two adjacent biomarker levels. The PAL can be used to generate pre-test prevalence-sensitive PAL plots that visualize the interplay between the probability of disease and the risk of missing a patient with the disease at specific biomarker levels.
Materials and methods

Simulations
Simulations were done in Excel 2011 for Mac OS 2011. Biomarker data from healthy individuals were retrieved from the Nordic Reference Interval Project 2000 (NORIP) database [13] (n ranging from 952 to 2740 for the 18 biomarkers analyzed). Diseased populations were simulated by scaling, where a fixed factor was added to each lab data from the NORIP database. These simulated disease data were used to assess the sampling error of PAL.
The sampling error is the variation in PAL when PAL is repeatedly calculated, typically 1000 times, from randomly selected subgroups of data. If the data in the subgroups are randomly selected with replacements called bootstrapping, each randomly selected subgroup of data will essentially be unique.
In these calculations, data with or without the added factor were randomly sampled with replacements. In each bootstrap, 100 authentic lab data from the NORIP database from individuals without disease and 100 lab data with the added factor (i.e., the simulated diseased population) were randomly selected.
From the bootstrapped data the Sn and the Sp were calculated at 21 biomarker limits derived from percentiles from the bootstrapped data (Supplemental Fig. 1) .
The Sn and the Sp were either the fraction of data above or below the 21 percentiles (non-parametric PAL calculation) or the integrated area under the normal distribution at the 21 percentiles using the mean and standard deviation (SD) from log-transformed data (parametric PAL calculation, Supplemental Fig. 1 ).
The Sn and the Sp were used to calculate the PAL at 20 regions; consequently, each PAL calculation included 5% of the combined bootstrapped data from healthy and simulated diseased populations. The mean and the 2.5th and the 97.5th percentiles of the Sn, Sp and PAL from 1000 bootstraps were plotted to examine the general trend and the sampling error of the different methods to calculate the Sn, Sp and PAL.
Analysis of PAL of high-sensitive cardiac troponin T
The study cohort comprised 11,020 visits to the emergency department (ED) at Mölndal or Östra Hospital at the Sahlgrenska University Hospital in Göteborg, Sweden, with a chief complaint of chest pain between January 2010 and December 2013. A characterization of admitted patients with chest pain at these EDs from another time period has been published before [14, 15] . Only males with creatinine levels below 100 μmol/L were included, as kidney function strongly affects cardiac troponin levels [16] . This resulted in the exclusion of 601 patients who lacked a creatinine measurement in the laboratory database. Until the end of January 2012, the hs-cTnT cutoff point for myocardial infarction (MI) was 40 ng/L. In February 2012, the hs-cTnT cutoff point for MI was changed to 14 ng/L. No point-of-care troponin assay was in use during the study and all troponin evaluations were made using the highsensitive cardiac troponin T assay (hs-cTnT) (Roche), analyzed by the central lab. The local performance of the hs-cTnT assay has been reported [17] . Only the first hs-cTnT analysis result recorded during each ED visit was used in Figs. 4 and 5. The final diagnosis of each ED visit was retrieved from the hospital registry. Laboratory data were retrieved from the local laboratory database. The study was approved by the Ethics Committee at the University of Gothenburg. The calculations of parametric and non-parametric Sn, Sp and PAL were made using Excel 2011 for Mac OS 2011, as described in the text on log-transformed hs-cTnT data. hs-cTnT limits were derived from 16 percentiles across the MI cohorts.
Results and discussion
If the pre-test prevalence of disease is 50%, then the PPV, the probability of disease above a given biomarker level, can be calculated from the Sn and Sp. Fig. 1 for details). The PAL is the disease prevalence (numbers) in the shaded area between the two biomarker levels. D. Visual representation of the sampling error of the PAL in relation to the PPV from 20 normally distributed simulated patient data without (green dots) or with (red dots) disease at a 50% disease prevalence. The numbers are the PAL calculated from data between the two biomarker levels and the PPV calculated from data above the action limit, indicated by black vertical lines. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
If the odds of not having the disease are included in this equation, a prevalence-adjusted PPV (PAP(+)) can be calculated at any disease prevalence [9, 10] :
where β is is the ratio of patients with the disease to those without the disease.
The same principle can be used to calculate the disease prevalence between two biomarker levels, the predictive value among lookalikes (PAL) (Fig. 1C, Supplemental Fig. 1) :
where Sn Low and Sn High are the sensitivity and, Sp Low and Sp High are the specificity at the adjacent lower and upper biomarker limits, respectively. If the range between the upper and the lower biomarker level includes the biomarker level found in a patient, the probability of disease can be estimated in a pre-test-sensitive way.
However, calculation of the PAL only involves study data between the upper and lower biomarker limits. For that reason, the PAL sampling error (see Materials and methods) may become unacceptably large if the number of study data or the distance between the two adjacent biomarker levels is small (Fig. 1D ).
We find, however, that the overall trend of how the PAL changes with biomarker levels is stable with an acceptable sampling error if the biomarker limits for the PAL are derived from percentiles. We have tested this using 21 limits across bootstrapped data sets of 100 lab data without disease and 100 simulated lab data with disease, so that the 20 PAL calculations involve at least 5% of the data (Fig. 2) . This was done in order to avoid erratic sampling errors [18] , if the Sp or the Sn is close to zero at the low or high end of the data sets.
The 95% confidence limits of the PAL grow wider as the data from individuals without disease are amplified with the β factor in the PAL equation (Fig. 2) . This is particularly evident if the data have a lognormal distribution like bilirubin (Fig. 2B) .
It is possible to plot the 1-Sn against the PAL (Fig. 3) . The resulting PAL plot behaves like a ROC plot. The advantage, compared with the ROC plot, is that the data on the longitudinal axis are affected by pretest prevalence and that the data on the horizontal axis describe the risk of missing the disease (1-Sn). Therefore, the area under the PAL plot (AUC) is dependent both on the pre-test prevalence and the biomarkers' ability to separate patients with and without disease ( Fig. 3) In this setting, a biomarker that fails to separate individuals with or without disease generates a PAL plot with a horizontal line at the disease prevalence. The horizontal line gives an AUC of 0.5 at a 50% disease prevalence (Fig. 3A) and an AUC of 0.1 at a 10% disease prevalence (Fig. 3B) . A perfect separation of individuals with or without disease generates an AUC close to 1 at any disease prevalence. Unlike ROC Fig. 3 . Comparison of a PAL plot and ROC plot analysis. Frequency plots of creatinine (n = 2636) levels from a healthy population (green lines) and a simulated diseased population (red lines) at a 50% (A) and a 10% (B) disease prevalence. The separation between the green and red population was made to generate an area under the ROC curve (AUC) of 0.5, 0.95 and 0.99. The magenta PAL (upper) and ROC plots (lower) are means from 1000 bootstraps of 100 lab data from the green and the red populations. The nonparametric 95% confidence limits from 1000 bootstraps are shown with thin black lines. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) plots, PAL plots visualize the interplay between the pre-test-dependent disease prevalence and the risk of missing the disease at specific biomarker levels.
To be able to calculate the PAL at the patient's specific biomarker level, we propose to use parametric Sp and Sn. The Sp and the Sn are proportions that can be estimated from the cumulative area under the normal distribution function.
Sn
where x is the biomarker level, SD no disease and SD disease is the standard deviation, and M no disease and M disease is the mean from the study data for individuals with or without the disease (Supplemental Fig. 1 ).
As biomarkers often display non-Gaussian distribution, the parametric estimates of the Sp and the Sp are often better when using logtransformed data (Fig. 4 ). With the parametric approach using logtransformed data, the goodness of fit with the non-parametric PAL and sampling error (see Materials and methods) are often acceptable when the parametric PAL is calculated from 100 authentic lab data without disease and 100 simulated lab data with disease (Supplemental Figs. 2-4 ). However, for some biomarkers, like creatine kinase, AST and bilirubin, the parametric PAL is unable to generate an acceptable fit (Supplemental Figs. 2-4 ), as these biomarkers do not follow a normal or log-normal distribution when analyzed with Q-Q plot and P-P plot (data not shown).
In addition, the sampling error of a parametric PAL increases to a larger extent compared with a non-parametric PAL when the data from individuals without disease are amplified by the β factor (Supplemental Figs. 2-4 ). However, if the Sp and the Sn are defined in a mathematical equation, the PAL can be calculated at patientspecific biomarker levels.
The pre-test prevalence is a missing factor. Sometimes, the pre-test prevalence is known. For instance, the pre-test prevalence of MI is often 5%, if a patient presents with chest pain at an emergency department in Sweden [14] . It is, however, important to note that the pretest prevalence depends on the clinical setting. It is likely that the chance of MI being present given a set of symptoms will be different in an emergency department with an efficient triage process than in a primary care setting.
The pre-test prevalence is often estimated using different score systems, like Well's score for deep venous thrombosis [19] . However, score systems use clinical findings and binary classification to calculate the probability of disease. Score systems are therefore also affected by the pre-test prevalence. Hence, at a given Well's score, the risk of deep venous thrombosis will be different, if Wells score is applied in an emergency department with an efficient triage or in a primary care setting. This possibly contributes to the variation in deep venous thrombosis prevalence of 0-38% at a moderate Well's score in validation studies [20] .
A promising possibility is to use local hospital statistics to identify stable baseline parameters, like chief complaint, age and gender, which distinguish between patients with different pre-test disease prevalences. Local hospital statistics and laboratory data can be used to calculate the PAL for a biomarker in these risk categories, as we have done for myocardial infarction (MI) and the myocardial infarction biomarker, high-sensitive cardiac troponin T (hs-cTnT) ( Figs. 4 and 5) . PAL plot analysis on this chest pain population shows that at a given chance of missing MI (1-Sn), the probability of MI is not very different among older and younger chest pain patients (Fig. 5) . Apparently, the lower Sp of the hs-cTnT test due to non-specific minor hs-cTnT elevations among older patients (Fig. 5B) [21] is balanced by a higher pretest prevalence of MI in older patients (Fig. 5E ). According to the PAL plot, the hs-cTnT test ability to distinguish chest pain patients with or without MI was similar at different ages, a fact not visualized by the ROC plot analysis (Fig. 5D ).
It is, however, important to note that these PAL calculations were made using non-parametric Sn and Sp, and can therefore not be applied to individual patients. In addition, the PAL for hs-cTnT must be further validated in a separate cohort prior to clinical use.
In summary, the PAL and PAL plots can visualize the interplay between "what fraction of patients with the disease will I miss if I exclude using my patient's biomarker value?" and "what is the probability of disease in my patient?" and thereby complement decision limits.
